Telix Pharmaceuticals: PSMA Radiopharmaceutical Player Is Revving Up (NASDAQ:TLX)
· seekingalpha.com
Telix Pharmaceuticals Limited Q1 revenue $230M, FY26 guidance reaffirmed, pipeline/PSMA progress and partnerships drive momentum. Click for more on TLX stock.
Analyst’s Disclosure: I/we have a beneficial long position in the shares of TLX either through stock ownership, options, or other derivatives. I wrote this ar...